Associated Disease Details
| Disease ID: | I01 |
| DO ID: | 552 |
| Disease Name: | Pneumonia |
| Definition: | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia |
| Synonyms: | Haemophilus influenzae pneumonia; Haemophilus parainfluenzae pneumonia; Legionella pneumophila pneumonia; Moraxella catarrhalis pneumonia; Mycoplasma pneumonia; Pneumonia due to Klebsiella pneumoniae; Pneumonia due to Staphylococcus aureus; Pneumonia, Bacterial; Streptococcal pneumonia; acute pneumonia; COVID-19 |
| Class: | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease |
| Related Drugs: | Amoxicillin; Azithromycin; CLA; Doxycycline |
| Mechanism: | NAFLD can play a role in the outcome of COVID-19 illness due to frequent association with comorbidities. Initial evidences suggest that increased liver fibrosis in NAFLD might affect COVID-19 outcome. In addition, long-term monitoring of post-COVID-19 NAFLD patients is advisable, to document further deterioration of liver damage. Further studies are required in this field. |
| Reference (PMIDs): | 32589264 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D010 | Amoxicillin | Chemical drug | DB01060 | -- | -- | Under clinical trials | Details |
| D025 | Azithromycin | Chemical drug | DB00207 | -- | -- | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D114 | Doxycycline | Chemical drug | DB00254 | -- | -- | Under clinical trials | Details |
| D342 | Solithromycin | Chemical drug | DB09308 | NF-kB inhibitor | Antibiotic drug, anti-inflammatory | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0023 | DB00080 | approved; investigational | small molecule | Daptomycin | Indication associated | Details |
| R0073 | DB00199 | approved; investigational; vet_approved | small molecule | Erythromycin | Indication associated | Details |
| R0085 | DB00218 | approved; investigational | small molecule | Moxifloxacin | Indication associated | Details |
| R0094 | DB00250 | approved; investigational | small molecule | Dapsone | Therapeutic strategy associated | Details |
| R0109 | DB00303 | approved; investigational | small molecule | Ertapenem | Indication associated | Details |
| R0131 | DB00365 | approved; investigational; withdrawn | small molecule | Grepafloxacin | Indication associated | Details |
| R0146 | DB00438 | approved | small molecule | Ceftazidime | Indication associated | Details |
| R0148 | DB00440 | approved; vet_approved | small molecule | Trimethoprim | Indication associated | Details |
| R0151 | DB00447 | approved; investigational; withdrawn | small molecule | Loracarbef | Indication associated | Details |
| R0158 | DB00467 | approved; investigational | small molecule | Enoxacin | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00320 | 35138548 | Intern Emerg Med | NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. | Details |
| A02299 | 34431511 | Cochrane Database Syst Rev | Vitamin D supplementation for chronic liver diseases in adults. | Details |
| A02820 | 34230921 | MedComm (2020) | Sex differences in clinical characteristics and risk factors for disease severity of hospitalized patients with COVID-19. | Details |
| A02967 | 34181776 | Aliment Pharmacol Ther | Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. | Details |
| A03059 | 34149320 | GastroHep | Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? | Details |
| A03256 | 34069176 | Life (Basel) | Kaempferol-3-O-Glucuronide Ameliorates Non-Alcoholic Steatohepatitis in High-Cholesterol-Diet-Induced Larval Zebrafish and HepG2 Cell Models via Regulating Oxidation Stress. | Details |
| A03363 | 34027561 | Arch Toxicol | Infections at the nexus of metabolic-associated fatty liver disease. | Details |
| A03446 | 33996143 | J Virus Erad | Prevention and control measures significantly curbed the SARS-CoV-2 and influenza epidemics in China. | Details |
| A03509 | 33977096 | Can J Gastroenterol Hepatol | NAFLD and Infection, a Nuanced Relationship. | Details |
| A03620 | 33928009 | Clin Nephrol Case Stud | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma. | Details |
| A03731 | 33887125 | United European Gastroenterol J | Gut fermentation syndrome: A systematic review of case reports. | Details |
| A04596 | 33569476 | Ann Transl Med | A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases. | Details |
| A05026 | 33406286 | Int J Clin Pract | Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. | Details |
| A05533 | 33216772 | PLoS One | Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. | Details |
| A06043 | 33031439 | PLoS One | In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. | Details |
| A06471 | 32867260 | Medicina (Kaunas) | Probiotics: Versatile Bioactive Components in Promoting Human Health. | Details |
| A06531 | 32838396 | MedComm (2020) | Radiomics-based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) and influenza A infected pneumonia. | Details |
| A06623 | 32803716 | Indian J Gastroenterol | Poor outcomes in patients with cirrhosis and Corona Virus Disease-19. | Details |
| A06821 | 32734407 | Hepatol Int | Effect of COVID-19 on patients with compensated chronic liver diseases. | Details |
| A06841 | 32727662 | Gastroenterol Hepatol | COVID-19 and liver disease: An update. | Details |